{"id":132585,"date":"2026-07-21T09:45:11","date_gmt":"2026-07-21T09:45:11","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/132585\/"},"modified":"2026-07-21T09:45:11","modified_gmt":"2026-07-21T09:45:11","slug":"novo-nordisk-gulf-appoints-venkat-kalyan-as-general-manager","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/132585\/","title":{"rendered":"Novo Nordisk Gulf appoints Venkat Kalyan as General Manager"},"content":{"rendered":"<p>      &#13;<br \/>\n  &#13;<br \/>\n  <img loading=\"lazy\" decoding=\"async\" class=\"gd-picture__img gd-picture__img--responsive\" src=\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/07\/04eac40f2545-venkat-kalyan-general-manager-for-novo-nordisk-gulf.webp\" width=\"950\" height=\"633\" alt=\"Venkat Kalyan, General Manager, Novo Nordisk Gulf. Image Courtesy: Novo Nordisk\"\/>&#13;<\/p>\n<p>    Venkat Kalyan, General Manager, Novo Nordisk Gulf. Image Courtesy: Novo Nordisk<\/p>\n<p>&#13;<br \/>\n    &#13;<br \/>\n    The appointment reinforces the company\u2019s confidence in the Gulf\u2019s evolving healthcare ecosystem&#13;\n  <\/p>\n<p>&#13;<br \/>\n    &#13;<br \/>\n    Press Release&#13;\n  <\/p>\n<p id=\"eXHvy1uasnn\">Dubai, UAE \u2013 Novo Nordisk has appointed Mr. Venkat Kalyan as General Manager\u00a0for\u00a0Novo Nordisk Gulf. The appointment reinforces the company\u2019s confidence in the Gulf\u2019s evolving healthcare ecosystem and the UAE\u2019s growing role as a strategic centre for medical research, innovation, and partnership-led growth.<\/p>\n<p id=\"ezWnf7pGFG0l\">In this role, Mr. Kalyan will oversee Novo Nordisk\u2019s operations across the UAE, Qatar, Kuwait, Bahrain, Oman, and Yemen. He will focus on strengthening healthcare partnerships, advancing innovation, and improving outcomes for patients living with chronic diseases.<\/p>\n<p id=\"em7AsaV8KXGb\">Mr. Kalyan commented: \u201cThe Gulf markets hold real potential and are exceptionally well positioned to lead the next phase of healthcare transformation. I look forward to building on Novo Nordisk\u2019s strong foundation in the region and working closely with all our healthcare stakeholders to improve outcomes for patients.\u201d<\/p>\n<p id=\"edYK-5ufczqd\">Mr. Kalyan brings nearly 30 years of experience in the pharmaceutical and healthcare sector, including 18 years at Novo Nordisk, most recently as General Manager of the Gulf Emerging Markets Cluster. His prior leadership experience spans across diverse markets such as India, Switzerland, Denmark, Middle Africa, South Africa and \u00a0Gulf countries.<\/p>\n<p id=\"ehrYNp9Vtkpo\">With its rapidly evolving healthcare landscape, the Gulf markets have become an integral part of Novo Nordisk\u2019s global growth strategy, as the company renews its commitment to expanding its impact across the region and advancing accessible and sustainable patient care systems for these communities.<\/p>\n<p id=\"ediPoMH9wvvd\">About Novo Nordisk<\/p>\n<p id=\"eOJ0QuT7bIUU\">Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 67,900 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube. \u00a0<\/p>\n<p>Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an \u201cas is\u201d and \u201cas available\u201d basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.<\/p>\n<p>\u00a9 ZAWYA 2026<\/p>\n","protected":false},"excerpt":{"rendered":"&#13; &#13; &#13; Venkat Kalyan, General Manager, Novo Nordisk Gulf. Image Courtesy: Novo Nordisk &#13; &#13; The appointment&hellip;\n","protected":false},"author":2,"featured_media":132586,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[272,21306],"class_list":["post-132585","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-novo-nordisk","tag-pharmaceutical"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116957330482225850","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/132585","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=132585"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/132585\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/132586"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=132585"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=132585"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=132585"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}